249 related articles for article (PubMed ID: 27340142)
1. Deoxycholic Acid (ATX-101) for Reduction of Submental Fat.
Dunican KC; Patel DK
Ann Pharmacother; 2016 Oct; 50(10):855-61. PubMed ID: 27340142
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study.
Ascher B; Hoffmann K; Walker P; Lippert S; Wollina U; Havlickova B
J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1707-15. PubMed ID: 24605812
[TBL] [Abstract][Full Text] [Related]
3. ATX-101 for reduction of submental fat.
Wollina U; Goldman A
Expert Opin Pharmacother; 2015 Apr; 16(5):755-62. PubMed ID: 25724831
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of injectable deoxycholic acid for submental fat reduction: a systematic review and meta-analysis of randomized controlled trials.
Cunha KS; Lima F; Cardoso RM
Expert Rev Clin Pharmacol; 2021 Mar; 14(3):383-397. PubMed ID: 33523775
[No Abstract] [Full Text] [Related]
5. REFINE-1, a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial With ATX-101, an Injectable Drug for Submental Fat Reduction.
Jones DH; Carruthers J; Joseph JH; Callender VD; Walker P; Lee DR; Subramanian M; Lizzul PF; Gross TM; Beddingfield FC
Dermatol Surg; 2016 Jan; 42(1):38-49. PubMed ID: 26673433
[TBL] [Abstract][Full Text] [Related]
6. ATX-101 (deoxycholic acid injection) for reduction of submental fat.
Ascher B; Fellmann J; Monheit G
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1131-43. PubMed ID: 27457304
[TBL] [Abstract][Full Text] [Related]
7. Management of Patient Experience With ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat.
Dover JS; Kenkel JM; Carruthers A; Lizzul PF; Gross TM; Subramanian M; Beddingfield FC
Dermatol Surg; 2016 Nov; 42 Suppl 1():S288-S299. PubMed ID: 27787269
[TBL] [Abstract][Full Text] [Related]
8. ATX-101 for reduction of submental fat: A phase III randomized controlled trial.
Humphrey S; Sykes J; Kantor J; Bertucci V; Walker P; Lee DR; Lizzul PF; Gross TM; Beddingfield FC
J Am Acad Dermatol; 2016 Oct; 75(4):788-797.e7. PubMed ID: 27430612
[TBL] [Abstract][Full Text] [Related]
9. A phase I safety and pharmacokinetic study of ATX-101: injectable, synthetic deoxycholic acid for submental contouring.
Walker P; Fellmann J; Lizzul PF
J Drugs Dermatol; 2015 Mar; 14(3):279-87. PubMed ID: 25738850
[TBL] [Abstract][Full Text] [Related]
10. Reduction of unwanted submental fat with ATX-101 (deoxycholic acid), an adipocytolytic injectable treatment: results from a phase III, randomized, placebo-controlled study.
Rzany B; Griffiths T; Walker P; Lippert S; McDiarmid J; Havlickova B
Br J Dermatol; 2014 Feb; 170(2):445-53. PubMed ID: 24147933
[TBL] [Abstract][Full Text] [Related]
11. The Use of Deoxycholic Acid for the Clinical Reduction of Excess Submental Fat in Indian Patients.
Shome D; Khare S; Kapoor R
J Drugs Dermatol; 2019 Mar; 18(3):266-272. PubMed ID: 30909331
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of ATX-101 by Treatment Session: Pooled Analysis of Data From the Phase 3 REFINE Trials.
Dayan SH; Schlessinger J; Beer K; Donofrio LM; Jones DH; Humphrey S; Carruthers J; Lizzul PF; Gross TM; Beddingfield FC; Somogyi C
Aesthet Surg J; 2018 Aug; 38(9):998-1010. PubMed ID: 29401213
[TBL] [Abstract][Full Text] [Related]
13. A Double-Blind, Placebo-Controlled, Phase 3b Study of ATX-101 for Reduction of Mild or Extreme Submental Fat.
Glogau RG; Glaser DA; Callender VD; Yoelin S; Dover JS; Green JB; Breshears L; Bowen B
Dermatol Surg; 2019 Dec; 45(12):1531-1541. PubMed ID: 30998531
[TBL] [Abstract][Full Text] [Related]
14. Overview of ATX-101 (Deoxycholic Acid Injection): A Nonsurgical Approach for Reduction of Submental Fat.
Dayan SH; Humphrey S; Jones DH; Lizzul PF; Gross TM; Stauffer K; Beddingfield FC
Dermatol Surg; 2016 Nov; 42 Suppl 1():S263-S270. PubMed ID: 27787266
[TBL] [Abstract][Full Text] [Related]
15. Non-Submental Applications of Injectable Deoxycholic Acid: A Systematic Review.
Sung CT; Lee A; Choi F; Juhasz M; Mesinkovska NA
J Drugs Dermatol; 2019 Jul; 18(7):675-680. PubMed ID: 31334926
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ATX-101 as a treatment for submental fullness: A retrospective analysis of two aesthetic practices.
Zarbafian M; Karavan M; Greene R; Fabi SG
J Cosmet Dermatol; 2020 Jun; 19(6):1328-1332. PubMed ID: 31553141
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 pharmacokinetic study of ATX-101: serum lipids and adipokines following synthetic deoxycholic acid injections.
Walker P; Lee D
J Cosmet Dermatol; 2015 Mar; 14(1):33-9. PubMed ID: 25684122
[TBL] [Abstract][Full Text] [Related]
18. The development, evidence, and current use of ATX-101 for the treatment of submental fat.
Georgesen C; Lipner SR
J Cosmet Dermatol; 2017 Jun; 16(2):174-179. PubMed ID: 28429841
[TBL] [Abstract][Full Text] [Related]
19. ATX-101 (Deoxycholic Acid Injection) Treatment in Men: Insights From Our Clinical Experience.
Shridharani SM; Behr KL
Dermatol Surg; 2017 Nov; 43 Suppl 2():S225-S230. PubMed ID: 28902021
[TBL] [Abstract][Full Text] [Related]
20. Current status of localized submental fat treatment with sodium deoxicolate (ATX-101).
Ibáñez-Vicente C; Carrato-Gomez M; Meccariello L; Ripani U; Bisaccia M
Med Glas (Zenica); 2021 Feb; 18(1):148-152. PubMed ID: 33655744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
